RU2016144076A - Сильнодействующие и селективные ингибиторы вируса гепатита с - Google Patents

Сильнодействующие и селективные ингибиторы вируса гепатита с Download PDF

Info

Publication number
RU2016144076A
RU2016144076A RU2016144076A RU2016144076A RU2016144076A RU 2016144076 A RU2016144076 A RU 2016144076A RU 2016144076 A RU2016144076 A RU 2016144076A RU 2016144076 A RU2016144076 A RU 2016144076A RU 2016144076 A RU2016144076 A RU 2016144076A
Authority
RU
Russia
Prior art keywords
alkyl
compound according
aryl
hcv
substituents
Prior art date
Application number
RU2016144076A
Other languages
English (en)
Russian (ru)
Inventor
Стивен Джей КОАТС
Ричард Энтони ВИТАКЕР
Тамара Росарио МАКБРАЙЕР
Цзюньсин ШИ
Фрэнк АМБЛАРД
Хонван ЧЖАН
Лонху ЧЖОУ
Реймонд Ф. ШИНАЗИ
Original Assignee
Кокристал Фарма, Инк.
Эмори Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кокристал Фарма, Инк., Эмори Юниверсити filed Critical Кокристал Фарма, Инк.
Publication of RU2016144076A publication Critical patent/RU2016144076A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2016144076A 2014-04-15 2015-04-15 Сильнодействующие и селективные ингибиторы вируса гепатита с RU2016144076A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
US61/980,016 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
RU2016144076A true RU2016144076A (ru) 2018-05-16

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016144076A RU2016144076A (ru) 2014-04-15 2015-04-15 Сильнодействующие и селективные ингибиторы вируса гепатита с

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101492672B1 (ko) * 2008-02-13 2015-02-16 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
CA2751458C (en) * 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112013004520A2 (pt) * 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
MX2013004906A (es) * 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Also Published As

Publication number Publication date
SG11201608587QA (en) 2016-11-29
IL248318A0 (en) 2016-11-30
KR20170002407A (ko) 2017-01-06
CA2945514A1 (en) 2015-10-22
JP2017513852A (ja) 2017-06-01
WO2015160907A2 (en) 2015-10-22
US20170029407A1 (en) 2017-02-02
EP3131892A2 (en) 2017-02-22
EP3131892A4 (en) 2017-09-20
BR112016023833A2 (pt) 2017-10-10
MX2016013434A (es) 2017-03-03
WO2015160907A3 (en) 2016-12-01
AU2015247706A1 (en) 2016-10-27
PH12016502039A1 (en) 2017-01-09
US9926295B2 (en) 2018-03-27
CN106661004A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
JP2019507774A5 (enExample)
EA201201031A1 (ru) Ингибиторы вируса гепатита с
JP2017523169A5 (enExample)
JP2016518434A5 (enExample)
JP2017537949A5 (enExample)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
JP2016518437A5 (enExample)
RU2014113539A (ru) Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
RU2012146986A (ru) Цефемовые соединения, содержащие катехольную группу
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
RU2015123641A (ru) 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний
JP2017508789A5 (enExample)
ME01882B (me) 1 '-supstituisani-karba-nukleozidni prolekovi za antivirusni tretman
JP2015500843A5 (enExample)
JP2017505314A5 (enExample)
RU2012117829A (ru) Фосфорамидатные производные нуклеозидов
JP2014511892A5 (enExample)
JP2019500387A5 (enExample)
JP2016503797A5 (enExample)
JP2016523955A5 (enExample)
RU2014107484A (ru) ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2
RU2008139195A (ru) Замещенные арилсульфанамиды как противовирусные средства
RU2018112312A (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
SI3166925T1 (en) Isoindoline derivatives for use in treating a viral infection